Pharmaceutics includes the manufacture, preparation, and marketing of medicines and heavily depends on research and development for its growth. A significant improvement in the available treatments is possible due to the continued investment in innovation made in the sector, which has led to the development of new drugs, an increase in life expectancy, and many diseases being treated. In a nutshell, the innovations of new medicines have saved millions of lives. 

‍

However, only 1 in 5,000 drug candidates finally get marketing approval in the pharmaceutical industry. According to the Congressional Budget Office, the expected cost to develop a new drug—including capital costs and expenditures on drugs that fail to reach the market—has been estimated to take up to more than $2 billion. 

‍

Lotus Pharmaceutical, a pacesetter in the industry, is changing the status quo by deploying a multidimensional strategy to build a unique portfolio and enable profitable growth; now, it has grown into one of the fastest-growing speciality generic companies in Asia and the largest pharma company in Taiwan with high-value generic products. 

‍

The company has demonstrated its pioneering position in the sector through experienced and reputable collaborations and regards partnerships as valuable assets. CEO of Lotus, Peter Vazharov, affirms, “The partnership is the cornerstone of our strategy, and it is our philosophy as a company.”

‍

Meanwhile, undertaking the ambitious mission of bringing higher-quality but lower-cost alternatives to patients worldwide, Róbert Wessman, Chairman of Lotus, says, “We fuel our business by coming with new products through our R&D, and we will continue to expand into new therapeutics and new technologies.”

‍

The company has a solid and well-diversified portfolio, mainly in its critical therapeutic field, oral oncology. Lotus focuses on producing a new generation of small-molecule medicines, gradually replacing traditional injectables. Mr. Wessman elaborates, “We will most likely see that oral oncology grows 50% overall in the next three years, and proportionally it is growing faster than the average.” Most advanced regulatory authorities worldwide have certified its oral oncology drugs, including the US FDA, EU EMA, and Brazil ANVISA.

‍

Carrying the firm ethos of “access is equally important as innovation,” Lotus has proven its capacity by offering a broad reach of nearly every global market through its high-value pipeline of direct markets and strategic alliances with top-tier pharma companies. It established vast partnerships with over 80 partners covering 131 countries and has invested tremendously in R&D in universities and research centres. Bjartur Shen, the Strategies and Finance Vice President of Lotus, explains, “In the last five years, we have invested over $50 million in the manufacturing of the sites and R&D Center in Nantou, Taiwan.”

‍

Even with its well-presented successes of having 20 strategically selected projects in development and registrations across Asia and the US and possessing more than 250 products in the market, Lotus Pharmaceutical is always aiming for more and beyond for the development of the industry and the welfare of the people. As Mr.Vazharov suggests, “the critical success factor in continuing with Lotus’ powerful performance is to stay hungry for opportunities.”